Compare Honeywell International Inc (HON) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell International Inc vs Moderna, Inc. — how do they compare? Honeywell International Inc trades at $207.86 (market cap $65.48B), while Moderna, Inc. trades at $220.56 (market cap $78.65B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Honeywell International Inc pays a 1.36% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell International Inc for 90 Days and Moderna, Inc. for 59 Days on average.
| HON | MRNA | |
|---|---|---|
Market Cap | $65.48B | $78.65B |
Volume | 2,047,782 | 37,373,437 |
Sector | Industrials | Health |
52-Week High | $248.79 | $203.46 |
52-Week Low | $188.14 | $22.36 |
Typical Hold Time | 90 Days | 59 Days |
Enterprise Value | $90.27B | $74.80B |
Dividend Yield | 1.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Honeywell International (HON) trades at $208.12 with minimal daily movement, showing strong profitability metrics including 21.6% net margin and 47.4% ROE. The company recently completed a strategic split into three focused businesses and secured a $300 million refinery project, positioning for growth in automation. Technical indicators show bearish momentum with support at $205 and resistance at $208, while fundamentals reveal attractive valuation with P/E of 7.9x below industry averages.
HON presents a compelling value opportunity with analyst consensus target of $259.25 representing 25% upside potential. The company's post-spin growth story is gaining momentum with recent earnings beats, though investors should monitor debt levels that have increased to 47.7% of assets and potential execution risks from the corporate restructuring.
Moderna (MRNA) trades at $214.50, up 9.17% with strong technical momentum. The stock shows bullish moving average signals despite negative profitability metrics, with revenue declining from $18.9B in 2022 to $1.92B in 2025. Recent Nasdaq-100 inclusion creates institutional demand, though Citigroup downgraded to Sell citing valuation concerns after a 500% 2026 rally. The company continues beating EPS expectations despite net losses.
Outlook remains bifurcated between technical strength and fundamental challenges. The cancer vaccine pipeline offers growth potential, but persistent losses and high valuations create headwinds. Near-term momentum may continue from index fund inflows, though profitability concerns warrant caution for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
